Stock Taper 
AirSculpt Technologies, Inc. operates as a holding company providing minimally invasive body contouring and fat transfer procedures across 19 centers in the U.S. using its AirSculpt method.
AirSculpt® is a minimally invasive, needle-free body contouring procedure that permanently removes fat and tightens skin with a quick 24-48 hour recovery, using proprietary technology to reduce invasiveness compared to traditional liposuction.
AirSculpt Technologies reported disastrous third-quarter 2025 results, with both earnings per share and revenue falling significantly short of analyst expectations. The company posted a net loss of $9.5 million and subsequently lowered its full-year 2025 revenue guidance to $153 million from a previous range of $160-$170 million, signaling deep operational challenges. This announcement triggered a massive sell-off and intense scrutiny from investors and analysts.
In 2025, AirSculpt Technologies initiated a significant strategic shift to address the aesthetic needs of the rapidly growing number of consumers using GLP-1 weight-loss medications. The company is introducing new services, including skin tightening pilot programs, to cater to patients experiencing skin laxity and other body contouring concerns following significant weight loss.
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 CMPS | $11.32 | COMPARE |
 AMN | $35.54 | COMPARE |
 INNV | $9.17 | COMPARE |
 MLTX | $10.10 | COMPARE |
 SIBN | $18.65 | COMPARE |
 PACB | $2.26 | COMPARE |
 AQST | $4.76 | COMPARE |
 CYH | $2.75 | COMPARE |
